These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 37249220)

  • 1. Osteonecrosis in Gaucher disease in the era of multiple therapies: Biomarker set for risk stratification from a tertiary referral center.
    Basiri M; Ghaffari ME; Ruan J; Murugesan V; Kleytman N; Belinsky G; Akhavan A; Lischuk A; Guo L; Klinger K; Mistry PK
    Elife; 2023 May; 12():. PubMed ID: 37249220
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Timing of initiation of enzyme replacement therapy after diagnosis of type 1 Gaucher disease: effect on incidence of avascular necrosis.
    Mistry PK; Deegan P; Vellodi A; Cole JA; Yeh M; Weinreb NJ
    Br J Haematol; 2009 Nov; 147(4):561-70. PubMed ID: 19732054
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk factors for fractures and avascular osteonecrosis in type 1 Gaucher disease: a study from the International Collaborative Gaucher Group (ICGG) Gaucher Registry.
    Khan A; Hangartner T; Weinreb NJ; Taylor JS; Mistry PK
    J Bone Miner Res; 2012 Aug; 27(8):1839-48. PubMed ID: 22692814
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incremental biomarker and clinical outcomes after switch from enzyme therapy to eliglustat substrate reduction therapy in Gaucher disease.
    Kleytman N; Ruan J; Ruan A; Zhang B; Murugesan V; Lin H; Guo L; Klinger K; Mistry PK
    Mol Genet Metab Rep; 2021 Dec; 29():100798. PubMed ID: 34485083
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Budget Impact Analysis of Eliglustat for the Treatment of Gaucher Disease Type 1 in the United States.
    Nalysnyk L; Sugarman R; Cele C; Uyei J; Ward A
    J Manag Care Spec Pharm; 2018 Oct; 24(10):1002-1008. PubMed ID: 30247105
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bone manifestations in neuronopathic Gaucher disease while receiving high-dose enzyme replacement therapy.
    Potnis KC; Flueckinger LB; Ha CI; Upadia J; Frush DP; Kishnani PS
    Mol Genet Metab; 2019 Feb; 126(2):157-161. PubMed ID: 30448006
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact on bone microarchitecture and failure load in a patient with type I Gaucher disease who switched from Imiglucerase to Eliglustat.
    Sidhu K; Boyd SK; Khan A
    Mol Genet Metab Rep; 2020 Sep; 24():100606. PubMed ID: 32509532
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glucosylsphingosine is a key biomarker of Gaucher disease.
    Murugesan V; Chuang WL; Liu J; Lischuk A; Kacena K; Lin H; Pastores GM; Yang R; Keutzer J; Zhang K; Mistry PK
    Am J Hematol; 2016 Nov; 91(11):1082-1089. PubMed ID: 27441734
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enzyme replacement and substrate reduction therapy for Gaucher disease.
    Shemesh E; Deroma L; Bembi B; Deegan P; Hollak C; Weinreb NJ; Cox TM
    Cochrane Database Syst Rev; 2015 Mar; 2015(3):CD010324. PubMed ID: 25812601
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modeling changes in biomarkers in Gaucher disease patients receiving enzyme replacement therapy using a pathophysiological model.
    Vigan M; Stirnemann J; Caillaud C; Froissart R; Boutten A; Fantin B; Belmatoug N; Mentré F
    Orphanet J Rare Dis; 2014 Jun; 9():95. PubMed ID: 24980507
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Brazilian Rare-Disease Center's Experience with Glucosylsphingosine (lyso-Gb1) in Patients with Gaucher Disease: Exploring a Novel Correlation with IgG Levels in Plasma and a Biomarker Measurement in CSF.
    Vernet Machado Bressan Wilke M; Iop GD; Faqueti L; Lemos da Silva LA; Kubaski F; Poswar FO; Michelin-Tirelli K; Randon D; Borelli WV; Giugliani R; Schwartz IVD
    Int J Mol Sci; 2024 Mar; 25(5):. PubMed ID: 38474117
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glucosylsphingosine (Lyso-Gb
    Gayed MM; Jung SH; Huggins E; Rodriguez-Rassi E; DeArmey S; Kishnani PS; Stiles AR
    Int J Mol Sci; 2022 Nov; 23(23):. PubMed ID: 36499264
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biochemical response to substrate reduction therapy versus enzyme replacement therapy in Gaucher disease type 1 patients.
    Smid BE; Ferraz MJ; Verhoek M; Mirzaian M; Wisse P; Overkleeft HS; Hollak CE; Aerts JM
    Orphanet J Rare Dis; 2016 Mar; 11():28. PubMed ID: 27008851
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The International Collaborative Gaucher Group GRAF (Gaucher Risk Assessment for Fracture) score: a composite risk score for assessing adult fracture risk in imiglucerase-treated Gaucher disease type 1 patients.
    Deegan P; Khan A; Camelo JS; Batista JL; Weinreb N
    Orphanet J Rare Dis; 2021 Feb; 16(1):92. PubMed ID: 33602299
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and efficacy of eliglustat combined to enzyme replacement therapy for lymphadenopathy in patients with Gaucher disease type 3.
    Lee NC; Chien YH; Wang CH; Wong SL; Peng SS; Tsai FJ; Hwu WL
    Mol Genet Metab Rep; 2022 Jun; 31():100867. PubMed ID: 35782609
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term velaglucerase alfa treatment in children with Gaucher disease type 1 naïve to enzyme replacement therapy or previously treated with imiglucerase.
    Smith L; Rhead W; Charrow J; Shankar SP; Bavdekar A; Longo N; Mardach R; Harmatz P; Hangartner T; Lee HM; Crombez E; Pastores GM
    Mol Genet Metab; 2016 Feb; 117(2):164-71. PubMed ID: 26043810
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-Term Evaluation of Biomarkers in the Czech Cohort of Gaucher Patients.
    Malinová V; Poupětová H; Řeboun M; Dvořáková L; Reichmannová S; Švandová I; Murgašová L; Kasper DC; Magner M
    Int J Mol Sci; 2023 Sep; 24(19):. PubMed ID: 37833892
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gaucher disease and its treatment options.
    Bennett LL; Mohan D
    Ann Pharmacother; 2013 Sep; 47(9):1182-93. PubMed ID: 24259734
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The clinical course of untreated Gaucher disease in 22 patients over 10 years: hematological and skeletal manifestations.
    Piran S; Roberts A; Patterson MA; Amato D
    Blood Cells Mol Dis; 2009; 43(3):289-93. PubMed ID: 19793665
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pulmonary vascular disease in Gaucher disease: clinical spectrum, determinants of phenotype and long-term outcomes of therapy.
    Lo SM; Liu J; Chen F; Pastores GM; Knowles J; Boxer M; Aleck K; Mistry PK
    J Inherit Metab Dis; 2011 Jun; 34(3):643-50. PubMed ID: 21445609
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.